Home›Stocks›IRMD

IRMD — structural market context

iRadimed Corporation

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 3 close to the Nov 4 close: +9.21%.

Volume

1.54× its 20-session average on Nov 4.

Includes pre- and post-market trading.

Short interest

Short interest 670K shares (settlement Oct 15) vs 657K (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Oct 1–Oct 14, published Nov 3): no fails listed.

Previous file (settlements Sep 15–Sep 30, published Oct 16): 2 days with fails, largest 61 shares on Sep 25.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

Events · early sample

None recorded in this window.

IRMD events and their magnitude

Latest SEC filing in the event study

8-K 2.02 · Earnings release · filed 2026-10-30 · View on sec.gov ↗

…

How the Event Study works →

IRMD short interest & days to cover

SHARES SHORT

670K

% OF FLOAT

8.0%

DAYS TO COVER

6.2

CHANGE VS PRIOR

+1.9%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)

How short interest and days to cover are measured →

IRMD fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-09-25 · 41d	61	$85.2
2026-09-15 · 51d	12	$82.53
2026-08-25 · 72d	47	$87.18

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

IRMD insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 2 sales

Insider	Type	Shares	Value	Filed
ALLEN MONTY K · director	Sale (S)	1K	$88K	2026-09-08
ALLEN MONTY K · director	Sale (S)	405	$35K	2026-09-08

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

IRMD analyst ratings

Firm	Action	Rating	Published
Needham	initialise	Hold	2026-09-22

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is IRMD's short interest?

As of the FINRA settlement date 2026-10-15, IRMD had 670K shares sold short — 8.0% of its float, with 6.2 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.

Are insiders buying IRMD?

In the last 12 months of SEC Form 4 filings, IRMD recorded 0 insider purchases and 2 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.

What do analysts say about IRMD?

The most recent action: Needham initialise to Hold on 2026-09-22. Rating actions are shown as published by the firms; they are not graded here.

Is this page telling me to buy or sell IRMD?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker The platform

Other companies in the same SEC industry: Surgical & Medical Instruments & Apparatus

BBNX · Beta Bionics, Inc.BSX · Boston Scientific Corp.KIDS · OrthoPediatrics Corp.LUNG · Pulmonx Corporation SOLV · Solventum Corporation BDX · Becton, Dickinson and Co.

Industry: SIC code 3841 as recorded on SEC EDGAR.

All tickers starting with I →

IRMD: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.